Symptoms of psoriatic arthritis are similar to rheumatoid arthritis and include, pain, swelling and stiffness in one or more ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more here.

In some cases, it can lead to psoriatic arthritis (PsA), which affects the ... speak with a doctor if they have any new or worsening signs of psoriasis or PsA. If individuals have psoriasis ...

Active psoriatic arthritis; Active non-radiographic axial spondyloarthritis with objective signs of inflammation; and Active ankylosing spondylitis. Findings showed treatment with bimekizumab led ...

Please see Important Safety Information below. Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are lifelong conditions that can have a significant impact on those diagnosed, particularly in ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

Treatment for arthritis is mainly focused on symptom management and slowing the progression of the disease, says Dr Vishal ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.